Large Molecule Bioanalytical Testing Services Market Worth $3.5 Billion By 2030

Large Molecule Bioanalytical Testing Services Market Growth & Trends

The global large molecule bioanalytical testing services market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 9.1% over the forecast period, according to a new report by Grand View Research, Inc. The increased use of bioanalytical testing in clinical trials of biomarkers, large molecules, and other substances is the main driver of the industry. The rising incidence of chronic diseases and the rising demand for clinical trials in developing nations are the factors driving the market growth. For instance, according to the WHO, around 10 million people died from cancer in 2020. As per the estimates of cancer, 30.2 million people are likely to have cancer by 2040. Other factors that are anticipated to drive the segment growth include a rise in biologics, high demand for advanced technologies, and the need for personalized orphan drugs & medicines.

It is also projected that factors like technological advancement, globalization of clinical trials, and the rising need for CROs to perform clinical trials will accelerate industry expansion. Large pharmaceutical and bioanalytical firms, however, encountered difficulties as a result of the COVID-19 pandemic, which hampered clinical studies and treatments. Along with the workload of the COVID-19 project, which involves starting clinical trials, preclinical testing, doing bioanalysis, and interacting with regulatory bodies, other difficulties include the loss of workers at sites. The non-Covid initiatives were delayed, and there were lengthy 4-6 month wait times as a result of the resources being used to support the bioanalytical, preclinical, and clinical testing for the Covid trials. They must also resolve assays that are related to Covid and those that are not.

 Request a free sample copy or view the report summary: Large Molecule Bioanalytical Testing Services Market Report

Large Molecule Bioanalytical Testing Services Market Report Highlights

• The clinical segment dominated the global industry in 2021. The growing prevalence of chronic diseases and increasing demand for clinical trials in developing countries are factors expected to drive segment growth

• The ADA-type segment dominated the global industry in 2021 and accounted for the largest share of the overall revenue

• Bioavailability was the largest test segment share in 2021 on account of the increasing adoption in generic drug manufacturing

• The oncology segment held the largest revenue share in 2021 due to the increasing prevalence of cancer globally

• Asia Pacific is projected to witness the fastest CAGR during the forecast years due to the rising healthcare expenditure, particularly in India and China

Large Molecule Bioanalytical Testing Services Market Segmentation

Grand View Research has segmented the global large molecule bioanalytical testing services market based on phase, type, test type, therapeutic areas, end-user, and region:

Large Molecule Bioanalytical Testing Services Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Preclinical

  • With Antibody

  • Without Antibody (ELISA Based Assay)

• Clinical

Large Molecule Bioanalytical Testing Services Type Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmacokinetics

• ADA

• Others

Large Molecule Bioanalytical Testing Services Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• ADME

• PD

• Bioavailability

• Bioequivalence

• Other Tests

Large Molecule Bioanalytical Testing Services Therapeutic Areas Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Infectious Diseases

• Cardiology

• Neurology

• Others

Large Molecule Bioanalytical Testing Services End-user Outlook (Revenue, USD Million, 2018 - 2030)

• SMEs

  • CROs & CMOs

  • Sponsor Organizations

  • Others (Academic Institute, etc.)

• Large Firms

  • CROs & CMOs

  • Sponsor Organizations

  • Others (Academic Institute, etc.)

Large Molecule Bioanalytical Testing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

  • Colombia

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

List of Key Players in the Large Molecule Bioanalytical Testing Services Market

• Covance

• IQVIA

• Syneos Health

• SGS SA

• Toxikon

• Intertek Group plc

• Pace Analytical Services LLC

• ICON Plc

• Charles River Laboratories

• Thermo Fisher Scientific